Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
Purpose: To assess the noninferiority, efficacy, and safety of degarelix in achieving and maintaining testosterone at castrate levels (≤0.5 ng/mL) in Korean patients (CS42) versus non-Asian patients with prostate cancer (PCa). Methods: A Phase III, open-label, multicenter, single-arm trial was condu...
Main Authors: | Dalsan You, Byung Ha Chung, Sang Eun Lee, Choung-Soo Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-03-01
|
Series: | Prostate International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888215000069 |
Similar Items
-
ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN
by: A. S. Markova, et al.
Published: (2014-07-01) -
ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN
by: A. S. Markova, et al.
Published: (2014-07-01) -
Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
by: Wook Nam, et al.
Published: (2018-01-01) -
The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer
by: Massimo Perachino, et al.
Published: (2013-09-01) -
Degarelix and its therapeutic potential in the treatment of prostate cancer
by: Christian Doehn, et al.
Published: (2009-05-01)